What development phase is Flenac in?

Flenac is FDA-approved (marketed).

What is the generic name of Flenac?

FENCLOFENAC is the generic (nonproprietary) name of Flenac.

Last reviewed 2026-04-20 · How we verify

Flenac (FENCLOFENAC)

FDA-approved withdrawn Small molecule Quality 6/100

Fenclofenac (Flenac) is a marketed nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) to reduce pain and inflammation. Its key strength lies in its well-established mechanism of action and the protection afforded by its key composition patent, which expires in 2028. The primary risk is the potential increase in competition following the patent expiry, which could impact market share and revenue.

At a glance

Generic name	FENCLOFENAC
Drug class	fenclofenac
Modality	Small molecule
Therapeutic area	Pain
Phase	FDA-approved
First approval	1978

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
FDA label	Mechanism, indications, dosing, boxed warnings, drug interactions

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Flenac CI brief — competitive landscape report
Flenac updates RSS · CI watch RSS